BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25338486)

  • 1. Hepatitis C virus-specific T-cell response correlates with hepatitis activity and donor IL28B genotype early after liver transplantation.
    Tsuzaki R; Takaki A; Yagi T; Ikeda F; Koike K; Iwasaki Y; Shiraha H; Miyake Y; Sadamori H; Shinoura S; Umeda Y; Yoshida R; Nobuoka D; Utsumi M; Nakayama E; Fujiwara T; Yamamoto K
    Acta Med Okayama; 2014; 68(5):291-302. PubMed ID: 25338486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication.
    Barbera F; Russelli G; Pipitone L; Pietrosi G; Corsale S; Vizzini G; Gridelli B; Conaldi PG
    New Microbiol; 2015 Apr; 38(2):201-10. PubMed ID: 25938745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL28B genetic variation and hepatitis C virus-specific CD4(+) T-cell responses in anti-HCV-positive blood donors.
    Bes M; Sauleda S; Campos-Varela I; Rodriguez-Frias F; Casamitjana N; Homs M; Piron M; Quer J; Tabernero D; Guardia J; Puig L; Esteban JI
    J Viral Hepat; 2012 Dec; 19(12):867-71. PubMed ID: 23121365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.
    Charlton MR; Thompson A; Veldt BJ; Watt K; Tillmann H; Poterucha JJ; Heimbach JK; Goldstein D; McHutchison J
    Hepatology; 2011 Jan; 53(1):317-24. PubMed ID: 21254179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study.
    Mueller JL; King LY; Johnson KB; Gao T; Nephew LD; Kothari D; Simpson MA; Zheng H; Wei L; Corey KE; Misdraji J; Lee JH; Lin MV; Gogela NA; Fuchs BC; Tanabe KK; Gordon FD; Curry MP; Chung RT
    Clin Transplant; 2016 Apr; 30(4):452-60. PubMed ID: 26854475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of regulatory T-cell and hepatitis C viral antigen-specific immune response in recurrent hepatitis C after liver transplantation.
    Utsumi M; Takaki A; Umeda Y; Koike K; Napier SC; Watanabe N; Sadamori H; Shinoura S; Yoshida R; Nobuoka D; Yasunaka T; Nakayama E; Yamamoto K; Fujiwara T; Yagi T
    Transpl Immunol; 2014 Jun; 31(1):33-41. PubMed ID: 24907425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the cellular immune response in HIV/HCV patients with hemophilia during peginterferon/ribavirin therapy in southern China.
    Yingying L; Jiangrong W; Jing L
    Diagn Microbiol Infect Dis; 2014 Jan; 78(1):45-8. PubMed ID: 24183601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
    Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
    J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal association between increased virus-specific Th17 response and spontaneous recovery from recurrent hepatitis C in a liver transplant recipient.
    Seetharam AB; Borg BB; Subramanian V; Chapman WC; Crippin JS; Mohanakumar T
    Transplantation; 2011 Dec; 92(12):1364-70. PubMed ID: 22082818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
    Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors.
    Chin JL; Nicholas RM; Russell J; Carr M; Connell J; Stewart S; McCormick PA
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1110-2. PubMed ID: 22664940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
    Fernández-Carrillo C; Coto-Llerena M; González P; Crespo G; Mensa L; Caro-Pérez N; Gambato M; Navasa M; Forns X; Pérez-del-Pulgar S
    J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.
    Ferraris P; Chandra PK; Panigrahi R; Aboulnasr F; Chava S; Kurt R; Pawlotsky JM; Wilkens L; Osterlund P; Hartmann R; Balart LA; Wu T; Dash S
    Am J Pathol; 2016 Apr; 186(4):938-51. PubMed ID: 26896692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.